Mirum's Livmarli (maralixibat) significantly reduced cholestatic pruritus vs placebo in the Phase III EXPAND pediatric study.
Roche secures exclusive worldwide license to Rona Therapeutics' ALK7 RNAi obesity therapy in a deal worth up to $1.16B. Read ...
BioNTech's BNT113 misses Phase III PFS endpoint in HPV16-positive head and neck cancer. Read the full trial update and what ...
Visara licenses VIS-102 nerve growth factor therapy for neurotrophic keratitis in a USD 111m deal. Read the full story on ...
Undecimal Bio raises $18M seed funding to extend siRNA delivery beyond the liver. Discover how this biotech's DELiveri ...
MicuRx will out-license preclinical ADC MRX-23 to ClearideBio, plus a STOPIN platform deal, worth up to USD 974 million. Read the full deal breakdown now.
Massachusetts General Hospital will test vitamin K2 drug EPN-701 in a Phase II calciphylaxis trial funded by a $2.46 million ...
Sloan-Kettering Institute gets a $1.5M FDA grant to map therapeutic targets in ultra-rare sarcomas. Learn how it may advance ...
Remigromig met the non-inferiority endpoint vs ranibizumab in the BRUNELLO DME trial, but PDR adverse events were higher.
Enodia Therapeutics and Pfizer sign a research and license deal worth over $500M to develop Sec61 translocon inhibitors. Read ...
Explore how iOnctura's roginolisib locks PI3Kδ in an inactive state and shows 20.8-month median survival in metastatic uveal melanoma. Read the full study.
AMPfield's once-daily prifemilast beat apremilast on both co-primary endpoints in a Phase III psoriasis head-to-head trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results